新冠病毒感染后胆管病——肝移植的新适应证：病例报告。
Post-Covid-19 Cholangiopathy-A New Indication for Liver Transplantation: A Case Report.
机构信息
Division of Transplant Surgery, Department of Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin; Transplant Center, Froedtert & the Medical College of Wisconsin and Children's Wisconsin, Milwaukee, Wisconsin; Division of Gastroenterology and Hepatology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Division of Transplant Surgery, Department of Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin; Transplant Center, Froedtert & the Medical College of Wisconsin and Children's Wisconsin, Milwaukee, Wisconsin.
出版信息
Transplant Proc. 2021 May;53(4):1132-1137. doi: 10.1016/j.transproceed.2021.03.007. Epub 2021 Mar 12.
Liver injury is one of the nonpulmonary manifestations described in coronavirus disease 2019 (COVID-19). Post-COVID-19 cholangiopathy is a special entity of liver injury that has been suggested as a variant of secondary sclerosing cholangitis in critically ill patients (SSC-CIP). In the general population, the outcome of SSC-CIP has been reported to be poor without orthotopic liver transplantation (OLT). However, the role of OLT for post-COVID-19 cholangiopathy is unknown. We present a case report of a 47-year-old man who recovered from acute respiratory distress syndrome from COVID-19 and subsequently developed end-stage liver disease from post-COVID-19 cholangiopathy. The patient underwent OLT and is doing well with normal liver tests for 7 months. To our knowledge, this is the first case report of a patient who underwent successful liver transplantation for post-COVID-19 cholangiopathy.
肝损伤是 2019 冠状病毒病（COVID-19）描述的非肺部表现之一。COVID-19 后胆管病是肝损伤的一种特殊类型，被认为是危重症患者继发性硬化性胆管炎（SSC-CIP）的一种变异。在普通人群中，据报道，SSC-CIP 患者如果不进行肝移植（OLT），其预后很差。然而，COVID-19 后胆管病患者是否需要进行 OLT 尚不清楚。我们报告了一例 47 岁男性的病例，该患者从 COVID-19 导致的急性呼吸窘迫综合征中康复，随后因 COVID-19 后胆管病发展为终末期肝病。该患者接受了 OLT，并且在 7 个月时肝脏检查正常，恢复良好。据我们所知，这是首例 COVID-19 后胆管病患者成功接受肝移植的病例报告。
Zotero 插件